Adjuvant Therapy TrialsUrsem, Carling MD; Van Loon, Katherine MD, MPH; Venook, Alan MDThe Cancer Journal: May/June 2016 - Volume 22 - Issue 3 - p 196–198 doi: 10.1097/PPO.0000000000000188 Reviews Buy Abstract Author InformationAuthors Article MetricsMetrics In 2015, ramucirumab and TAS-102 became the 10th and 11th drugs approved by the Food and Drug administration for the treatment of patients with colorectal cancer, not counting leucovorin, and yet only 3 agents, 5-fluorouracil, capecitabine, and oxaliplatin, have proven benefit in adjuvant treatment. In fact, there have been no additions (and 1 subtraction levamisole) to our arsenal of therapies for patients with stages II and III colon cancer for more than a decade. How did we get here? Are we stuck? And how do we move forward? From the Gastrointestinal Oncology, University of California, San Francisco, CA. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Carling Ursem, MD, Gastrointestinal Oncology, 505 Parnassus Ave, Room M1286, University of California, San Francisco, CA 94143. E-mail: Carling.email@example.com. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.